Core Viewpoint - Invivyd positions its monoclonal antibody VYD2311 as a potent alternative to COVID-19 vaccination, emphasizing its potential for "vaccine-free protection" against symptomatic COVID-19 [1] Company Focus and Pipeline - The company is advancing its REVOLUTION clinical program for VYD2311, continuing the commercialization of PEMGARDA, and exploring additional clinical indications, including long COVID and other infectious diseases like RSV and measles [2][13] - Invivyd has completed enrollment in the pivotal DECLARATION trial for VYD2311, with results expected in mid-2026 [6][9] Financial Performance - Invivyd raised over $200 million in the second half of 2025, ending the year with $226.7 million in cash, which supports operations through pivotal data expected in mid-2026 [4][17] - PEMGARDA's net revenues increased by 31% quarter-over-quarter and 25% year-over-year, totaling $53.4 million for the full year 2025, with a reorder rate of 77% among accounts [5][16] Clinical Trials and Safety Monitoring - The DECLARATION trial is a triple-blind randomized clinical trial evaluating VYD2311's safety and efficacy, with a target enrollment of approximately 1,770 subjects [6][7] - The Independent Data Monitoring Committee has reviewed early safety data and made recommendations regarding participant enrollment and monitoring [7][10] Commercial Strategy - Invivyd is seeing increased clinician interest in monoclonal antibodies for high-risk patients, with PEMGARDA included in guidelines from major health organizations [11][12] - The company is expanding its commercial footprint, with over 15,000 contracted GPO sites [5][14] Future Developments - Invivyd is excited to explore antibodies for long COVID and post-vaccination syndrome, with plans for updates on measles in the first half of the year [13][15]

Financial Data and Key Metrics Changes - Invivyd's net revenues for Q4 2025 increased by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [26] - The company ended the year with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [26] Business Line Data and Key Metrics Changes - The commercial work with PEMGARDA showed growth in Q4, establishing a foundation for broader commercialization of VYD2311 if approved [5] - The company reported a high reorder rate of 77% for PEMGARDA, indicating strong ongoing demand [24] Market Data and Key Metrics Changes - There is a growing recognition of monoclonal antibodies in the medical community, with leading organizations recommending their use for high-risk patients [22] - The company has secured over 15,000 contracted GPO sites, significantly expanding its commercial footprint [24] Company Strategy and Development Direction - Invivyd aims to redefine COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [25] - The company is focusing on expanding its portfolio to include treatments for other infectious diseases, such as RSV and measles, indicating a broader strategic vision [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [18] - The company is optimistic about the speed of study recruitment and the potential for robust assessment of VYD2311's effectiveness [20] Other Important Information - Invivyd is conducting its third randomized placebo-controlled trial for a COVID monoclonal antibody, which is designed to adapt to virus evolution [14] - The company is exploring the use of monoclonal antibodies for long COVID and post-vaccination syndrome, highlighting its commitment to addressing unmet medical needs [7] Q&A Session Summary Question: Can you elaborate on the potential trial resizing decision in the DECLARATION program? - Management indicated that the resizing decision would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [29][30] Question: Are secondary endpoints being collected in the trial? - Management confirmed that various interactions, including healthcare utilization, would be recorded, but cautioned against expecting meaningful powering of low-frequency clinical events [34][35] Question: What is the envisioned use case for the measles antibody program? - Management highlighted potential use cases for outbreak prophylaxis and pediatric bridge therapy, emphasizing the antibody's design to address specific medical needs [37][41] Question: How is the DECLARATION study configured to target areas with high COVID rates? - Management explained that the study sites are strategically located in areas with community COVID attack rates, utilizing various data sources to inform site selection [46][48] Question: What is the approach to monitoring myocarditis in the study? - Management stated that the monitoring would primarily focus on clinical myocarditis events, with the possibility of further exploration if such events occur [50][51] Question: How does Invivyd plan to compete in the RSV antibody market? - Management expressed confidence in their antibody's properties and the potential to address evolutionary drift, positioning it as a competitive option in the RSV market [56][58]

Financial Data and Key Metrics Changes - Invivyd's net revenues for PEMGARDA grew by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [26] - The company ended 2025 with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [26] Business Line Data and Key Metrics Changes - The commercial activities for PEMGARDA are showing growth, establishing a foundation for broader commercialization of VYD2311 if approved [5][6] - The company is expanding its commercial footprint with over 15,000 contracted GPO sites, indicating a strong market presence [24] Market Data and Key Metrics Changes - There is a growing recognition among healthcare professionals of the importance of monoclonal antibodies for COVID prevention, as reflected in clinical guidelines from leading organizations [22][23] - The adoption curve for antibody therapy is expanding, particularly in specialties such as hematology, oncology, and infectious diseases [23] Company Strategy and Development Direction - Invivyd is focusing on redefining COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [25] - The company is also exploring clinical applications for long COVID and post-vaccination syndrome, indicating a strategic expansion into new therapeutic areas [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [18][21] - The company is optimistic about the speed of study recruitment and the potential for robust assessment of VYD2311's effectiveness [18] Other Important Information - The company has appointed Michael Mina as Chief Medical Officer, which may enhance its clinical and strategic capabilities [4] - The DECLARATION clinical trial for VYD2311 has reached its target enrollment, with potential for modest over-enrollment [16] Q&A Session Summary Question: Potential trial resizing decision in the DECLARATION program - Management indicated that the resizing decision would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [29][30][31] Question: Secondary endpoints being collected in the trial - Management confirmed that various interactions, including healthcare utilization, would be recorded, but cautioned against expecting meaningful powering of low-frequency clinical events [34][36] Question: Update on the measles antibody program - Management discussed potential use cases for the measles antibody, including outbreak prophylaxis and pediatric bridge therapy, emphasizing the need for innovative solutions in this area [37][38][42] Question: Myocarditis monitoring in the study - Management clarified that myocarditis monitoring would primarily be a yes/no exercise, with the possibility of further exploration if events occur [50][51] Question: Competition in the RSV antibody market - Management expressed confidence in their RSV antibody's competitive properties and the potential for success in a market that is still evolving [56][58]

Financial Data and Key Metrics Changes - Invivyd's net revenues for Q4 2025 increased by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [25] - The company ended the year with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [25] Business Line Data and Key Metrics Changes - The commercial activities with PEMGARDA showed growth in Q4, establishing a foundation for broader commercialization of VYD2311 if approved [5] - The company reported a high reorder rate of 77% for PEMGARDA, indicating strong ongoing demand [23] Market Data and Key Metrics Changes - There is a growing recognition among healthcare professionals of the importance of monoclonal antibodies for COVID prevention, as reflected in clinical guidelines from leading organizations [22] - Invivyd has secured over 15,000 contracted GPO sites, significantly expanding its commercial footprint [23] Company Strategy and Development Direction - Invivyd aims to redefine COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [24] - The company is focusing on expanding its portfolio to include treatments for other infectious diseases, such as RSV and measles, which could enhance its market presence [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [20] - The company is closely monitoring the evolving COVID landscape and is prepared to adapt its strategies based on community infection rates [46] Other Important Information - The DECLARATION clinical trial for VYD2311 has reached its target enrollment, with the potential for modest over-enrollment [16] - The company is excited about the potential of its RSV antibody, which is designed to compete with existing treatments in the market [54] Q&A Session Summary Question: Can you elaborate on the potential trial resizing decision in the DECLARATION program? - Management indicated that resizing would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [30][31] Question: Are secondary endpoints being collected in the DECLARATION study? - Management confirmed that various interactions, including healthcare utilization, will be recorded, although they cautioned against expecting meaningful powering for low-frequency clinical events [33][36] Question: What is the envisioned use case for the measles antibody program? - Management highlighted potential use cases including outbreak prophylaxis and pediatric bridge therapy, emphasizing the need for innovative solutions in pediatric care [37][39] Question: How is the DECLARATION study being configured to target areas with high COVID rates? - Management explained that they are utilizing community data to place study sites in areas with higher COVID attack rates, although they acknowledged the challenges of rapidly changing conditions [46] Question: What is the monitoring plan for myocarditis in the LIBERTY study? - Management stated that the monitoring will primarily be a yes/no exercise for overt myocarditis, with the possibility of further exploration if events occur [48]

Core Viewpoint - Invivyd, Inc. has published a peer-reviewed analysis demonstrating that clinical protection levels from COVID can be predicted based on laboratory-determined serum monoclonal antibody activity levels, regardless of virus variation, supporting the use of monoclonal antibodies in clinical decision-making and public health stewardship [1][2][3] Group 1: Clinical Trial Insights - The CANOPY Phase 3 clinical trial assessed the clinical protection of Invivyd's monoclonal antibody pemivibart in reducing symptomatic COVID, establishing a statistically derived correlate of protection curve that illustrates the relationship between antibody activity and protection from symptomatic disease [2][3][4] - The analysis indicates that clinical efficacy can be predicted from stable epitopes of monoclonal antibodies, showing meaningful protection even at low antibody levels, which aligns with normal human immune physiology [2][3][5] Group 2: Implications for Healthcare - The findings from the peer-reviewed analysis could accelerate regulatory pathways for monoclonal antibodies, potentially reducing the need for animal models or extensive trials, and expanding COVID-19 protection strategies beyond annual vaccine boosting [2][3][6] - The model provides a mechanism for healthcare professionals and regulators to quantify the relationship between monoclonal antibodies and clinical protection, facilitating better understanding and application in public health [6][2] Group 3: Product Information - PEMGARDA (pemivibart) is an investigational monoclonal antibody with a robust safety profile, demonstrating in vitro neutralizing activity against major SARS-CoV-2 variants and targeting the spike protein receptor binding domain to inhibit virus attachment [7][8] - The emergency use authorization (EUA) for PEMGARDA is specifically for pre-exposure prophylaxis in adults and adolescents with moderate-to-severe immune compromise, and it is not a substitute for vaccination [8][9]

Summary of Invivyd Conference Call Company Overview - **Company**: Invivyd - **Industry**: Monoclonal Antibody Therapeutics - **Key Product**: PEMGARDA, a monoclonal antibody for COVID prevention in immunocompromised individuals, currently under Emergency Use Authorization (EUA) [3][6] Core Points and Arguments Product Development - **Next-Generation Asset**: VYD2311 is set to enter pivotal trials for Biologics License Application (BLA), aiming for a transition from intravenous infusion (PEMGARDA) to intramuscular injection, which is expected to enhance patient access and ease of administration [3][4][18] - **RSV Candidate**: Invivyd is also developing a candidate for Respiratory Syncytial Virus (RSV), with plans for an Investigational New Drug (IND) application by late 2026 [4] Regulatory Pathway - **BLA Pathway**: Invivyd is working closely with the FDA to design a BLA-enabling trial, with plans to start patient enrollment by the end of 2023 or early 2024 [8][18] - **Primary Efficacy Endpoint**: The primary endpoint for the pivotal trial will be the number of PCR positive COVID cases in treatment versus placebo groups [19] Commercial Strategy - **Cost of Goods Sold (COGS)**: Invivyd targets pharmaceutical-like margins of over 80%, with expectations for VYD2311 pricing in the hundreds of dollars, significantly lower than PEMGARDA's current price of approximately $6,500 [16][17] - **Market Positioning**: The company believes VYD2311 could serve as a compelling alternative to vaccines, addressing vaccine hesitancy and safety concerns [22] Clinical Insights - **Potency and Dosage**: VYD2311 is expected to have a potency increase of 15-17 times compared to PEMGARDA, allowing for a lower dose of under 300 mg [15][36] - **Half-Life**: The half-life of VYD2311 is projected to be between 60 to 70 days, providing sufficient protection with a single dose [36] Additional Important Content - **Administration Setting**: VYD2311 could be administered in pharmacies or doctor's offices, similar to flu shots, enhancing accessibility [29] - **Future Developments**: Invivyd is considering multipurpose antibodies that could target multiple pathogens, although regulatory pathways would require initial products to be approved first [31][32] - **Patient Experience**: The administration of VYD2311 is expected to have fewer side effects compared to vaccines, with typical injection site reactions being the primary concern [24][25] Timeline and Expectations - **Data Package Submission**: Invivyd aims to submit a data package to the FDA by mid-2026, with potential market entry within a year following approval [39]

Financial Data and Key Metrics Changes - Invivyd's PEMGARDA revenues grew by 11% quarter-on-quarter and 41% year-over-year, reflecting ongoing market awareness efforts [19] - The company raised approximately $87 million in capital during the quarter, enhancing its financial position for upcoming clinical programs [5][19] Business Line Data and Key Metrics Changes - The commercial franchise for PEMGARDA is expanding, with over 15,000 contracted GPO sites and more than 1,200 sites offering infusion services, with 76% of those accounts reordering [14][15] - The company is transitioning from a smaller patient population to a broader market with the potential approval of VYD2311, aiming to replace current vaccine options [14][18] Market Data and Key Metrics Changes - COVID vaccine sales in the U.S. totaled $3.8 billion last year, indicating a significant market opportunity for Invivyd's products [18] - Current COVID vaccine uptake is substantially below that of influenza vaccines, despite higher public concern about COVID [17] Company Strategy and Development Direction - Invivyd is focused on advancing its next-generation antibody, VYD2311, which aims to provide a safer and more effective alternative to current COVID vaccines [4][18] - The company plans to initiate pivotal clinical studies for VYD2311 around year-end 2025, with top-line data expected in mid-2026 [7][13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming 12-18 months, highlighting the potential for significant advancements in COVID prevention for vulnerable populations [7] - The company aims to address safety concerns associated with COVID vaccines through its antibody-based approach, which is expected to have a favorable side effect profile [12][13] Other Important Information - The DECLARATION and LIBERTY studies are designed to provide critical data on the efficacy and safety of VYD2311 compared to existing vaccines [10][13] - Invivyd is also exploring early-stage discovery efforts in RSV and measles, with plans for rapid advancement into clinical development [31][33] Q&A Session Summary Question: Will Invivyd wind down PEMGARDA once the next-gen product is approved? - Management confirmed that there are no plans to actively sunset PEMGARDA, as it remains a differentiated medicine despite its scalability challenges [22] Question: Can you clarify the coordination between CBER and CDER for the LIBERTY study? - Management indicated that coordination between CBER and CDER is expected due to the unique nature of the study, but specific details are best addressed by the FDA [24][26] Question: What are the commercial team's current reach and plans for expansion? - The commercial team is building upon its foundation in infusion centers and plans to expand its reach through digital assets and increased field presence [30] Question: How does Invivyd intend to differentiate its early-stage discovery programs in RSV and measles? - Management highlighted the focus on viral resistance and biophysical properties as key differentiation factors for the new antibody programs [32][33]

Summary of Invivyd (IVVD) Conference Call - September 03, 2025 Company Overview - **Company**: Invivyd (IVVD) - **Product**: PEMGARDA, a monoclonal antibody authorized under Emergency Use Authorization for the prevention of COVID-19 in certain immunocompromised individuals [2][4] Core Points and Arguments 1. **Current Status**: Invivyd is a commercial-stage company with an authorized product, PEMGARDA, and is developing a next-generation monoclonal antibody, VYD2311, aimed at improving efficacy and safety compared to existing vaccines [2][3][4] 2. **Technological Advantage**: The company emphasizes its unique technology that allows for the evolution of antibodies to enhance their biophysical properties, which is expected to lead to better medical outcomes for patients [3][4] 3. **Regulatory Engagement**: Invivyd has had constructive dialogues with the FDA regarding the development of VYD2311, which is positioned as a potential alternative to vaccines for COVID-19 [4][5][22] 4. **Market Positioning**: The company aims to shift the reliance from vaccines to monoclonal antibodies for COVID-19 prevention, targeting both high-risk adults and pediatric populations [5][14] 5. **Clinical Efficacy**: PEMGARDA has shown an 85% to 94% reduction in the likelihood of getting sick, although it is described as a specialty medicine with logistical challenges for administration [8][10] 6. **Future Development**: The company plans to conduct clinical trials for VYD2311, which is expected to have a favorable product profile compared to vaccines, including higher efficacy, safety, and durability [24][25][39] 7. **Commercial Strategy**: Invivyd is focused on education and engagement with key opinion leaders and decision-makers to prepare for the commercialization of VYD2311 [40][41] 8. **Cost Structure**: The expected cost of goods sold (COGS) for VYD2311 is projected to be below $100, with a retail price potentially around several hundred dollars, aiming to provide a broad population medicine rather than a specialty product [44][45][46] Important but Overlooked Content 1. **Regulatory History**: The regulatory journey of PEMGARDA has been complex, with the FDA and EMA initially defining its role narrowly, which has impacted its market penetration [7][10] 2. **Public Perception**: The company acknowledges the challenges posed by public perception and misinformation regarding COVID-19 treatments and vaccines, emphasizing the need for clear communication of the benefits of monoclonal antibodies [28][30] 3. **Potential for Resistance**: Invivyd is aware of the potential for emerging resistance to antibodies but believes that their current product, VYD2311, will maintain efficacy due to its stable epitope [47][48] This summary encapsulates the key points discussed during the conference call, highlighting Invivyd's strategic direction, product development, and market positioning in the context of COVID-19 treatment.

Financial Data and Key Metrics Changes - The company reported net product revenue of $11.3 million for PEMGARDA in Q1 2025, with cash and cash equivalents of approximately $48 million at the end of the quarter [52] - Operating expenses decreased to $27.4 million in Q1 2025 from $32.3 million in Q4 2024, representing a 15% reduction quarter-over-quarter [52] Business Line Data and Key Metrics Changes - The transition to an internalized commercial organization is expected to drive broader adoption of PEMGARDA, with early indicators showing promise for revenue growth and expense management [6][9] - Although Q1 revenues dipped from Q4, the company anticipates positive momentum and early signs of acceleration in Q2, including the largest commercial day and week recorded [20][21] Market Data and Key Metrics Changes - The company is seeing increased interest from healthcare providers and institutions regarding PEMGARDA, with a focus on educating clinicians about its benefits [16][18] - The product is now included in the NCCN guidelines for B cell lymphomas, indicating recognition and acceptance within the medical community [22] Company Strategy and Development Direction - The company aims to create medical value for patients and translate that into shareholder value efficiently, focusing on disciplined capital management and operational proof of concept [9][10] - The strategic focus includes expanding the pipeline to multiple disease areas, including new viral targets and a discovery program for RSV monoclonal antibodies [7][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth of the PEMGARDA business, citing no obstacles in the evolutionary journey of SARS CoV-2 [6][7] - The company is adapting to a changing regulatory environment and is focused on maintaining its EUA while seeking to transition to a BLA [56][58] Other Important Information - The company has secured access to additional non-dilutive capital to support growth, contingent on meeting certain conditions and milestones [7] - A modest price increase for PEMGARDA was implemented in March, with the product still being one of the lowest-priced antibodies launched [24] Q&A Session Summary Question: Could you please characterize your recent interaction with the new agency regarding EUA? - The company prefers to move beyond the EUA construct and seeks to leverage unique contemporary efficacy data in discussions with the FDA [56][58] Question: Can you discuss the headwinds encountered in Q1 sales? - The transition to an internal sales team caused a disruption in field activity, but the company is seeing strong metrics and increased access to PEMGARDA [62][64] Question: Can you provide details on the measles program and its potential market size? - The measles program is part of the company's existing budget and aims to add value without significantly impacting cash reserves, focusing on long-term growth potential [70][71]

Financial Data and Key Metrics Changes - The company reported net product revenue of $11.3 million for PEMGARDA in Q1 2025, with cash and cash equivalents of approximately $48 million at the end of the quarter [52] - Operating expenses decreased to $27.4 million in Q1 2025 from $32.3 million in Q4 2024, representing a 15% reduction quarter-over-quarter [52] - The company anticipates continued reduction in operating expenses in Q2 2025 due to sufficient supply of PEMGARDA and VYD2311, with a target for profitability by the end of the first half of 2025 [52] Business Line Data and Key Metrics Changes - The transition to an in-house sales team has been completed, which is expected to drive consistent growth for PEMGARDA [13][52] - Although Q1 revenues dipped from Q4, the company is seeing positive momentum and early signs of acceleration in Q2, including the biggest commercial day and week recorded [18][52] Market Data and Key Metrics Changes - The company has expanded its commercial reach significantly, increasing the number of sites offering PEMGARDA from about 120 to over 880 [65] - The product is now included in the NCCN guidelines for B cell lymphomas, indicating growing recognition and acceptance in the medical community [20] Company Strategy and Development Direction - The company aims to create medical value for patients and translate that into shareholder value efficiently, focusing on disciplined capital management [8][9] - The strategic decision to internalize the sales force is part of a broader effort to enhance commercial capabilities and drive growth [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving near-term breakeven with continued revenue growth and effective operating expense management [5] - The company is optimistic about the long-term growth potential of its PEMGARDA business, supported by promising leading indicators [5][6] Other Important Information - The company has secured access to additional non-dilutive capital to support growth, contingent on meeting certain conditions and milestones [6] - The focus has shifted towards early measles discovery, reflecting a strategic pivot in response to emerging health challenges [7] Q&A Session Summary Question: Could you please characterize your recent interaction with the new agency regarding EUA? - The company prefers to move beyond the EUA construct and seeks to leverage contemporary efficacy data for potential BLA discussions with the FDA [56][58] Question: Could you please expand on the headwinds encountered in Q1? - The company faced disruptions due to the transition from a contract sales organization to an in-house team, but has seen positive metrics in Q2 [63][64] Question: Can you discuss the measles program and its development path? - The company is adding a measles discovery program without pivoting from existing priorities, aiming to create value for patients and shareholders [73][74]